As the GLP-1 injectable shortage enters its second year, countless patients have turned to compounded medications like tirzepatide and semaglutide to maintain their health. These solutions, prepared by licensed compounding pharmacies like MediVera Compounding Pharmacy™, have played a role in addressing manufacturing shortages.
However, access to these medications may be at risk. Drug manufacturers have requested that GLP-1 active pharmaceutical ingredients (APIs) be added to the FDA’s “demonstrably difficult to compound” list. If approved, this could restrict compounding pharmacies’ ability to prepare these medications, leaving patients without alternatives.
Why This Matters
Millions of patients rely on compounded GLP-1 medications as part of their healthcare plan. Here’s why preserving access is essential:
Tailored Treatments
Compounded medications provide individualized patient solutions, prepared under rigorous processes that meet USP 795, 797, and 800 standards.
Filling Gaps
Compounding has been critical in addressing shortages and ensuring patients receive necessary care.
Maintaining Options
Restricting GLP-1 compounding could reduce access to alternative therapies that some patients depend on for their health.
Secure the Future of Personalized Care – Take Action Now!
MediVera Compounding Pharmacy™ is dedicated to supporting patients and healthcare providers. Here’s how you can help:
- Patients Can Advocate for Access:
- Visit compounding.com/tellFDA.
- Use the pre-drafted letter, personalize it with your name and address, and send it to the FDA.
- Healthcare Professionals Can Share Their Expertise:
- Submit a letter to the FDA using customizable templates available online. Highlight the role of compounding in providing essential care.
This issue extends beyond GLP-1 medications. Decisions to restrict compounding may impact access to alternative therapies, reducing options for patients who benefit from personalized care.
At MediVera, we are committed to empowering patients and providers with treatment options that meet individual needs. Protecting access to compounded medications ensures flexibility and personalization remain core to healthcare.
Take action today to safeguard patient access and preserve the future of compounded therapies.
Join the fight to protect access to compounded GLP-1 medications. Send your letter to the FDA and safeguard personalized healthcare solutions!
